SHR116637

SHR116637 is a pharmacologically active **major circulating metabolite of famitinib**, created by the N-desethylation of famitinib. It exhibits similar but generally lower potency compared to the parent compound. Famitinib (and, by extension, SHR116637) is a small molecule tyrosine kinase inhibitor developed as an antineoplastic agent, targeting multiple receptor tyrosine kinases implicated in tumor angiogenesis and growth. SHR116637 has demonstrated pharmacological activity but with a plasma exposure level substantially lower (about 3.6%) than the parent drug. The clinical development and evaluation of SHR116637 are primarily as a metabolite in the pharmacokinetic and safety assessment of famitinib therapy[1][3][5].

Other names

N-desethyl famitinib